AstraZeneca Reports Phase 3 Data for Olaparib in Follicular lymphoma

AstraZeneca today announced Phase 3 results for olaparib in patients with follicular lymphoma. The study demonstrated that olaparib significantly improves overall survival compared to standard of care or placebo. These results provide important insights into the treatment of follicular lymphoma and support the continued development of olaparib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.